Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Conditions:   Blasts Under 5 Percent of Peripheral Blood White Cells;   Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level;   IDH2 Gene Mutation;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Enasidenib;   Procedure: Hematopoietic Cell Transplantation Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials